Enantioselective synthesis of primary 1-(aryl)alkylamines by nucleophilic 1,2-addition of organolithium reagents to hydroxyoxime ethers and application to asymmetric synthesis of G-protein-coupled receptor ligands

Journal of Organic Chemistry

Volumn 69, Issue 17, 2004, Pages 5595-5607

  Atobe, Masakazu ^a   Yamazaki, Naoki ^a   Kibayashi, Chihiro ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATION; CHEMICAL BONDS; ETHERS; REDUCTION; SYNTHESIS (CHEMICAL);

ENANTIOSELECTIVE SYNTHESIS; ORGANOLITHIUM REAGENTS;

STEREOCHEMISTRY;

(1 HYDROXY 2 PHENYLETHYL)ETHYLAMINE; (2 HYDROXY 1 PHENYLETHYL)ETHYLAMINE; 1 (2 HYDROXYPHENYL)ETHYLAMINE; 3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; ALIPHATIC AMINE; CALCIUM CHANNEL STIMULATING AGENT; ETHER DERIVATIVE; G PROTEIN COUPLED RECEPTOR; HYDROXYOXIME ETHER; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; NATURAL PRODUCT; NEUROKININ 1 RECEPTOR ANTAGONIST; ORGANOLITHIUM COMPOUND; UNCLASSIFIED DRUG; VINYLLITHIUM;

ADDITION REACTION; ARTICLE; CHEMICAL BOND; CHEMICAL MODIFICATION; CHIRALITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOSELECTIVITY; METHODOLOGY; REDUCTION;

AMINES; ANILINE COMPOUNDS; CALCIUM; ETHERS; LIGANDS; LITHIUM; MOLECULAR MIMICRY; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; PIPERIDINES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROKININ-1; STEREOISOMERISM;

EID: 4043070494     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo049517+     Document Type: Article

References (51)

1. For recent reviews, see: (a) Enders, D.; Reinhold, U. Tetrahedron: Asymmetry 1997, 8, 1895-1946.
2. (b) Bloch, R. Chem. Rev. 1998, 98, 1407-1438.
3. (c) Alvaro, G.; Savoia, D. Synlett 2002, 651-673.
4. Gilchrist, T. L. In Comprehensive Organic Synthesis; Trost, B. M., Ed.; Pergamon: Oxford, 1991; Vol. 8, pp 381-402.
5. (a) Ukaji, Y.; Kume, K.; Watai, T.; Fujisawa, T. Chem. Lett. 1991, 173-176.
6. (b) Rodriques, K. E.; Basha, A.; Summers, J. B.; Brooks, D. W. Tetrahedron Lett. 1988,29, 3455-3458.
7. (c) Brown, D. S.; Gallagher, P. T.; Lightfoot, A. P.; Moody, C. J.; Slawin, A. M. Z.; Swann, E. Tetrahedron 1995, 51, 11473-11488.
8. (d) Moody, C. J.; Lightfoot, A. P.; Gallagher, P. T. Synlett 1997,659-660.
9. (e) Moody, C. J.; Lightfoot, A. P.; Gallagher, P. T. J. Org. Chem. 1997, 62, 746-748.
10. (f) Gallagher, P. T.; Hunt, J. C. A.; Lightfoot, A. P.; Moody, C. J. J. Chem. Soc., Perkin Trans, 1 1997, 2633-2637.
11. For preliminary reports of a part of this work, see: (a) Yamazaki, N.; Atobe, M.; Kibayashi, C. Tetrahedron Lett. 2001, 42, 5029-5032.
12. (b) Yamazaki, N.; Atobe, M.; Kibayashi, C. Tetrahedron Lett. 2002, 43, 7979-7982.
13. For the synthesis of (+HK)-NPS R-568 (1), see: (a) Barmore, R. M.; Logan, S. R.; Van Wagenen, B. C. Tetrahedron Lett. 1998, 39, 3451-3454.
14. (b) Hansen, M. C.; Buchwald, S. L. Tetrahedron Lett. 1999, 40, 2033-2034.
15. Nemeth, E. F.; Van Wagenen, B. C.; Balandrin, M. F.; Delmar, E. G.; Moe, S. T. U.S. Patent 6001884, 1999; Chem. Abstr. 2000, 132, 35523.
16. For the asymmetric synthesis of (+)-CP-99,994, see: (a) Desai, M. C.; Lefkowitz, S. L.; Thadeio, P. F.; Longo, K. P.; Snider, R. M. J. Med. Chem. 1992, 35, 4911-4913.
17. (b) Chandrasekhar, S.; Mohanty, P. K. Tetrahedron Lett. 1999, 40, 5071-5072.
18. (c) Tsuritani, N.; Yamada, K.; Yoshikawa, N.; Shibasaki, M. Chem. Lett. 2002, 276-277.
19. For the synthesis of racemic CP-99,994, see: (a) Desai, M. C.; Thadeio, P. F.; Lefkowitz, S. L. Tetrahedron Lett. 1993,34, 5831-5834.
20. (b) Rosen, T.; Seeger, T. F.; Mclean, S.; Desai, M. C.; Guarino, K. J.; Bryce, D.; Pratt, K.; Heym, J. J. Med. Chem. 1993, 36, 3197-3201 (tritiated derivative).
21. For the synthesis of CP-122,721, see: Rosen, T. J.; Coffman, K. J.; McLean, S.; Crawford, R. T.; Bryce, D. K.; Gohda, Y.; Tsuchiya, M.; Nagahisa, A.; Nakane, M.; Lowe, J. A., III. Bioorg. Med. Chem. Lett. 1998, 8, 281-284.
22. Grochowski, E.; Jurezak, J. Synthesis 1978, 682-684.
23. When these condensations with 8 were run without the addition of TsOH, the same results were obtained, although prolonged reaction time (2-4 h) was necessary. (12) For diastereoselective Grignard addition to imine compounds involving chelation of metal alkoxides with the imine nitrogen, see: (a) Takahashi, H.; Tomita, K.; Noguchi, H. Chem. Pharm. Bull. 1881, 29, 3387-3391.
24. (b) Takahashi, H.; Inagaki, H. Chem. Pharm. Bull. 1882, 30, 922-926.
25. (c) Takahashi, H.; Hsieh, B. C.; Higashiyama, K. Chem. Pharm. Bull. 1980, 38, 2429-2434.
26. (d) Veith, U.; Leurs, S.; Jäger, V. Chem. Commun. 1995, 329-330.
27. For reviews, see: (a) Johnson, F. Chem. Rev. 1968, 68, 375-413.
28. (b) Hoffmann, R. W. Chem. Rev. 1889, 89, 1841-1860.
29. Cicchi, S.; Goti, A.; Brandi, A.; Guarna, A.; De Sarlo, F. Tetrahedron Lett. 1990, 31, 3351-3354.
30. (a) Yamazaki, N.; Ito, T.; Kibayashi, C. Tetrahedron Lett. 1999, 40, 739-742.
31. (b) Yamazaki, N.; Ito, T.; Kibayashi, C. Org. Lett. 2000, 2, 465-467.
32. (c) Yamazaki, N.; Dokoshi, W.; Kibayashi, C. Org. Lett. 2001. 3, 193-196.
33. (d) Itoh, T.; Yamazaki, N.; Kibayashi, C. Org. Lett. 2002. 4, 2469-2472.
34. Published procedure on the enantioselective synthesis of (+)- 1-(2-hydroxyphenyl)ethylamine [(S)-45] relied on asymmetric reduction of 2-benzyloxyacetophenone O-methyloxime, prepared in 77% yield from 2-hydroxyacetophenone, using an optically active amino-borane reagent. This led to (+)-1-(2-benzyloxyphenyl)ethylamine with 67% ee in 53% yield, which was debenzylated by hydrogenolysis to produce (S)-45. Yoneyoshi, Y.; Suzukamo, G.; Sakito, Y. Eur. Pat. Appl. EP 311,385, 1989; Chem. Abstr. 1990, 112, 35431z.
35. (a) Steffey, M. E.; Fox, J.; Van Wagenen, B. C.; Balandrin, M. F.; Nemeth, E. F. J. Bone Miner. Res. 1993, 8, S175.
36. (b) Silverberg, S. J.; Bone, H. G., III; Marriott, T. B.; Locker, F. G.; Thys-Jacobs, S.; Dziem, G.; Kaatz, E. L.; Sanguinetti, E. L.; Bilezikian, J. P. New Engl. J. Med. 1997, 337, 1506-1510.
37. (c) Nemeth, E. F.; Steffey, M. E.; Hammerland, L. G.; Hung, B. C. P.; Van Wagenen, B. C.; DelMar, E. G.; Balandrin, M. F. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4040-4045.
38. (a) von Euler, V. S.; Gaddum, J. H. J. Physiol. 1931, 72, 577-583.
39. (b) Chang, M. M.; Leeman, S. E. J. Biol. Chem. 1970, 245, 4784-4790.
40. (c) Pernow, B. Pharmacol. Rev. 1983,35, 85-141.
41. (d) Nakanishi, S. Physiol. Rev. 1987, 67, 1117-1142.
42. (e) Vaught, J. Life Sci. 1988, 43, 1419-1431.
43. (a) Watson, J. W.; Gonsalves, S. F.; Fossa, A. A.; McLea, S.; Seeger, T.; Obach, S.; Andrews, P. L. R. Br. J. Pharmacol. 1995, 115, 84-94.
44. (b) Zaman, S.; Woods, A. J.; Watson, J. W.; Reynolds, D. J. M.; Andrews, P. L. R. Neuropharmacology 2000, 39, 316-323.
45. Boks, G. J.; Tollenaere, J. P.; Kroon, J. Bioorg. Med. Chem. 1997, 5, 535-547.
46. McLean, S.; Ganong, A.; Seymour, P. A.; Bryce, D. K.; Crawford, R. T.; Morrone, J.; Reynolds, L. S.; Schmidt, A. W.; Zorn, S.; Watson, J.; Fossa, A.; DePasquale, M.; Rosen, T.; Nagahisa, A.; Tsuchiya, M.; Heym, J. J. Pharmacol. Exp. Ther. 1996, 277, 900-908.
47. Pallavicini, M.; Valoti, E.; Villa, L.; Piccolo, O. Tetrahedron: Asymmetry 2000, 11, 4017-4025.
48. Boeckman, R. K., Jr.; Shao, P.; Mullins, J. J.; Smith, A. B., III. Org. Synth. 1999, 77, 141-152.
49. Compound 64 has been prepared from (2S,3S)-63 by Swern oxidation; see: Kulagowski, J. J.; Curtis, N. R.; Swain, C. J.; Williams, B. J. Org. Lett. 2001, 3, 667-670
50. (a) Laschat, S.; Kunz, H. J. Org. Chem. 1991, 56, 5883-5889.
51. (b) Sunazuka, T.; Hirose, T.; Shirahata, T.; Harigaya, Y.; Hayashi, M.; Komiyama, K.; Omura, S. J. Am. Chem. Soc. 2000, 122, 2122-2123.